Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,041,362 | $2,100,071 | $2,738,299 | $5,118,304 |
| - Cash | $281,967 | $435,895 | $232,767 | $965,647 |
| + Debt | $161,425 | $172,689 | $179,005 | $142,350 |
| Enterprise Value | $1,920,820 | $1,836,865 | $2,684,537 | $4,295,007 |
| Revenue | $63,518 | $377,709 | $60,920 | $51,844 |
| % Growth | -83.2% | 520% | 17.5% | – |
| Gross Profit | -$304,043 | $377,709 | -$250,674 | -$180,290 |
| % Margin | -478.7% | 100% | -411.5% | -347.8% |
| EBITDA | -$393,643 | -$146,954 | -$324,332 | -$230,061 |
| % Margin | -619.7% | -38.9% | -532.4% | -443.8% |
| Net Income | -$376,742 | -$132,527 | -$289,088 | -$370,638 |
| % Margin | -593.1% | -35.1% | -474.5% | -714.9% |
| EPS Diluted | -4.58 | -1.72 | -4.13 | -5.77 |
| % Growth | -166.3% | 58.4% | 28.4% | – |
| Operating Cash Flow | -$347,246 | -$149,195 | $22,527 | -$66,268 |
| Capital Expenditures | -$8,946 | -$33,732 | -$48,951 | -$46,811 |
| Free Cash Flow | -$356,192 | -$182,927 | -$26,424 | -$113,079 |